XJB-5-131 is a synthetic, bi-functional antioxidant specifically designed to target mitochondria for the scavenging of reactive oxygen species (ROS) and electrons, thereby acting as a radical scavenger. Additionally, it serves as an effective protector and mitigator against ionizing irradiation for cord blood mononuclear cells (CB MNCs).

XJB-5-131 mitigates hemorrhagic shock (HS)-induced activation of caspases 3 and 7, key pro-apoptotic enzymes, in the ileal mucosa, thereby reducing apoptosis and enhancing cell survival, as evidenced in mouse embryonic cells in vitro. Additionally, it serves as an effective radiation shield, particularly for colony-forming unit-granulocyte macrophage (CFU-GM), displaying significant protective and mitigative effects when administered before or after irradiation. This is demonstrated by its capacity to increase the D0 to 1.93±0.13 for CFU-GM when provided as a treatment, highlighting its potential as a versatile agent in cellular protection and survival enhancement mechanisms.

XJB-5-131 mitigates peroxidation of cardiolipin, a key mitochondrial phospholipid, in rat ileal mucosal samples following hemorrhagic shock (HS)[1], and intravenous administration at 2 μmol/kg notably extends survival in rats experiencing severe blood loss (33.5 mL/kg), with minimal crystalloid solution volume (2.8 mL/kg) and no blood transfusion[1]. It also diminishes oxidative harm to mitochondrial DNA, upholds mitochondrial DNA quantity, halts motor function degradation and weight loss, augments neuronal preservation, and boosts mitochondrial efficiency. In a Huntington’s disease (HD) mouse model, XJB-5-131 significantly curtails disease phenotypes and enhances mitochondrial performance[2], and at a dosage of 1 mg/kg, given intraperitoneally three times weekly for up to 57 weeks, it counters weight and motor function decline[2]. Study specifics include utilization of male Sprague-Dawley rats (150 to 250 g)[1] with outcomes showing marked survival improvement (P < 0.01), and HD150KI mice for HD research[2], where chronic treatment inhibited weight reduction and elevated average body mass by 22%.